Attualità

IB research: “Ovarian induction in egg donors: Corifollitropin alfa versus urinary FSH”

  • 28-12-2015

In last years corifollitropin alfa (ElonvaTM) has been added to the treatments available to induce ovulation. It is especially designed to work much longer than conventional FSH, so that one single injection of Elonva can replace daily FSH injections. Furthermore it has been argued that recruitment of antral follicles can be improved because of its pharmacokinetics. Both features are of special interest in the egg donor group. 

Continui a leggere

We share with the scientist community our results from two years of experience on the validation of our Comprehensive Chromosome Screening (CCS)

  • 24-12-2015

In the last years, on the way to single embryo transfer (SET),  preimplantation genetic screening (PGS) using array technology to test embryo aneuploidy of all chromosomes in the blastocyst stage, is becoming the technique of choice to select the best embryo, increasing implantation rate and decreasing miscarriage.  

Continui a leggere

IB Research: Does blastocyst biopsy affect to the implantation potential of frozen-thawed chromosomally normal embryos?

  • 23-12-2015

Blastocyst biopsy for Comprehensive Chromosomal Screening (CCS) treatments can be addressed through different strategies. When biopsy on D+5 is performed, fresh transfer on day 6 is possible. There is also the option of freezing the embryos after the biopsy to delay the embryo transfer if circumstances such as inadequate endometrial preparation or high progesterone levels require it. The aim of this study is to determine which of these two strategies show better outcomes. Two groups were created depending whether a biopsy on day 5 and transfer on day 6 was performed.

Continui a leggere

IB Research on the Embryo Vitrification Model: optimizing the equilibration time.

  • 22-12-2015

Vitrification techniques are commonly used in In vitro fertilization (IVF) laboratories. The vitrification process includes a first step of embryo equilibration. This step never exceeds 15 minutes because cryoprotectans can produce embryo damage. The aim of this study is to establish a timing model to minimize the embryo exposure time to cryoprotectans solutions.

Continui a leggere